Seattle Genetics, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$138.8M
Doctors Paid
6,560
Transactions
35,824
2019 Total
$46.5M
Payment Breakdown by Category
Research$132.7M (95.6%)
Travel$850,449 (0.6%)
Food & Beverage$525,662 (0.4%)
Consulting$353,554 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $132.7M | 10,950 | 95.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3.0M | 1,095 | 2.1% |
| Honoraria | $860,578 | 314 | 0.6% |
| Travel and Lodging | $850,449 | 2,428 | 0.6% |
| Food and Beverage | $525,662 | 18,165 | 0.4% |
| Consulting Fee | $353,554 | 183 | 0.3% |
| Space rental or facility fees (teaching hospital only) | $280,887 | 188 | 0.2% |
| Grant | $156,196 | 25 | 0.1% |
| Education | $134,255 | 2,473 | 0.1% |
| Charitable Contribution | $4,000 | 3 | 0.0% |
Payments by Type
Research
$132.7M
10,950 transactions
General
$6.1M
24,874 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A single-arm, open-label, multicenter study of enfortumab vedotin ASG-22CE for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor CPI therapy | $7.7M | 23 | 1,606 |
| A Phase II Study Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone CHEP-BV Followed by BV Consolidation in Patients with CD30-Positive Peripheral T-cell Lymphomas | $7.3M | 0 | 37 |
| Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | $7.3M | 7 | 1,019 |
| A Phase II Trial of PET-Directed Therapy using AVD doxorubicin, vinblastine, and dacarbazine plus Brentuximab Vedotin Induction Chemotherapy Followed by Nivolumab Consolidation for Patients with Previously Untreated Non-bulky Limited Stage Hodgkin Lymphoma | $6.4M | 0 | 31 |
| A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin ASG-22CE in Combination With Pembrolizumab andor Chemotherapy for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer | $5.3M | 12 | 280 |
| A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and 30 Gy Involved-Site Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma | $5.0M | 0 | 26 |
| SG0350025 | $4.3M | 0 | 200 |
| A Phase II, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2 Metastatic Colorectal Cancer | $4.2M | 0 | 17 |
| Phase II , Multi-center Trial of Nivolumab and Brentuximab Vedotin in Patients with Untreated Hodgkin Lymphoma Over the Age of 60 Years or Unable to Receive Standard ABVD Chemotherapy | $4.0M | 0 | 28 |
| A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above | $3.7M | 0 | 586 |
| A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer | $3.6M | 0 | 865 |
| Phase 1b2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer | $3.5M | 0 | 408 |
| SG035IST032 | $3.1M | 0 | 27 |
| SG035IST018 | $3.1M | 0 | 19 |
| SG035IST021 | $2.7M | 0 | 16 |
| SG0350015 | $2.7M | 0 | 184 |
| A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies | $2.5M | 3 | 317 |
| Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | $2.3M | 8 | 212 |
| SG035IST029 | $2.3M | 0 | 22 |
| Adcetris brentuximab vedotin substituting for vincristine in the OEPACOPDac regimen Treatment group 3 TG3 of Euro-Net C1 with involved node radiation therapy for high risk pediatric hodgkin lymphoma | $2.2M | 0 | 15 |
| Phase II trial of Adcetris brentuximab vedotin in CD30 malignant mesothelioma | $2.2M | 0 | 12 |
| SG0CD33A0005 | $2.0M | 0 | 237 |
| A phase 1, multicenter, open-label, dose-escalation study of SGN 2FF in patients with advanced solid tumors | $1.6M | 5 | 206 |
| Phase II pilot study of brentuximab vedotin, rituximab and dose-attenuated CHP in elderly patients with diffuse large B cell lymphoma | $1.6M | 0 | 12 |
| Pediatric classical hodgkin lymphoma consortium study chod17 | $1.5M | 0 | 9 |
| SG0LIV1A0001 | $1.5M | 0 | 253 |
| A Phase 12 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy | $1.4M | 0 | 187 |
| SG035IST043 | $1.4M | 0 | 3 |
| A Pilot Study of Weekly Brentuximab Vedotin or Brentuximab Vedotin Plus Nivolumab Every 3 Weeks in Patients with CD30 Malignancies Refractory to Every 3 Week Brentuximab Vedotin | $1.2M | 0 | 9 |
| A phase III study of brentuximab vedotin, ifosfamide I, carboplatin C, and etoposide E, for relapsed or refractory Hodgkin lymphoma BV-ICE | $1.2M | 0 | 8 |
Payments by Medical Specialty
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2019 |
|---|---|---|---|---|
| Dr. Luis Pineiro, Md, MD | Medical Oncology | Dallas, TX | $39,968 | $0 |
| Dr. David Rizzieri, M.d, M.D | Medical Oncology | Charlotte, NC | $38,571 | $0 |
| Kelly Mccaul, M.d, M.D | Hematology & Oncology | Sioux Falls, SD | $36,587 | $0 |
| Dr. Alejandro Gru, Md, MD | Dermatopathology | New York, NY | $36,131 | $0 |
| John Pagel, Md Phd, MD PHD | Hematology & Oncology | Seattle, WA | $34,815 | $0 |
| Daniel Couriel, M.d, M.D | Hematology & Oncology | Salt Lake City, UT | $32,966 | $0 |
| Peter Odonnell | Internal Medicine | Chicago, IL | $31,924 | $0 |
| Adam Forman, Md, MD | Internal Medicine | Southfield, MI | $31,208 | $0 |
| Michael Schuster, Md, MD | Internal Medicine | New York, NY | $29,216 | $0 |
| Mehrad Abedi, M.d, M.D | Specialist | Sacramento, CA | $28,894 | $0 |
| Dr. Danko Martincic, Md, MD | Hematology | Post Falls, ID | $28,483 | $0 |
| Barbara Pro, M.d, M.D | Medical Oncology | New York, NY | $28,149 | $0 |
| Dr. Helen Ryan, Md, MD | Hematology & Oncology | Kennebunk, ME | $27,198 | $0 |
| Steven Horwitz, Md, MD | Medical Oncology | New York, NY | $26,535 | $0 |
| Joshua Brody, M.d, M.D | Hematology & Oncology | New York, NY | $26,141 | $0 |
| Dr. Lori Leslie, M.d, M.D | Hematology | Hackensack, NJ | $26,053 | $0 |
| Dr. Aaron Goodman, Md, MD | Hematology & Oncology | Las Vegas, NV | $25,886 | $0 |
| Dr. Javier Munoz, M.d., M.s., F.a.c.p, M.D., M.S., F.A.C.P | Internal Medicine | Phoenix, AZ | $25,770 | $0 |
| Dr. Kevin Kelly, M.d, M.D | Hematology & Oncology | Los Angeles, CA | $25,598 | $0 |
| Robert Chen, Md, MD | Hematology | Los Angeles, CA | $25,060 | $0 |
| Dr. Marin Xavier, Md, MD | Hematology & Oncology | San Diego, CA | $24,750 | $0 |
| John Burke, Md, MD | Hematology & Oncology | Aurora, CO | $23,561 | $0 |
| Christopher Hoimes, Do, DO | Hematology & Oncology | Cleveland, OH | $23,232 | $0 |
| Dr. Daniel Petrylak, M.d, M.D | Hematology & Oncology | New Haven, CT | $23,180 | $0 |
| Dr. Manali Kamdar, Md, MD | Hematology & Oncology | Aurora, CO | $21,163 | $0 |
Ad
Top Products
- ADCETRIS $75.2M
- SGN35 $4.5M
Associated Products (16)
Payment Categories
- Food & Beverage $525,662
- Consulting $353,554
- Travel & Lodging $850,449
- Research $132.7M
About Seattle Genetics, Inc.
Seattle Genetics, Inc. has made $138.8M in payments to 6,560 healthcare providers, recorded across 35,824 transactions in the CMS Open Payments database. In 2019, the company paid $46.5M. The top product by payment volume is ADCETRIS ($75.2M).
Payments were distributed across 103 medical specialties. The top specialty by payment amount is Hematology & Oncology ($2.5M to 2,789 doctors).
Payment categories include: Food & Beverage ($525,662), Consulting ($353,554), Research ($132.7M), Travel & Lodging ($850,449).
Seattle Genetics, Inc. is associated with 16 products in the CMS Open Payments database, including SGN35, 33ADC, and SGN19A.